If you are enrolled in a UnitedHealthcare Medicare Advantage plan, please visit this page
ICHANGE is committed to advancing the science of digestive, liver, and metabolic health through a robust research program that spans clinical trials, translational investigation, and basic science. Our goal is to accelerate discoveries that improve care for conditions driven by metabolic dysfunction and obesity.
We conduct clinical studies evaluating new medications, endoscopic procedures, and integrative treatment strategies. Participation in these trials allows eligible patients to access emerging therapies while contributing to evidence that informs future standards of care.
Our investigators collaborate across Weill Cornell Medicine to bridge laboratory discoveries with real-world patient care. These studies focus on metabolic pathways, inflammation, liver disease mechanisms, and predictors of treatment response — converting scientific insight into clinical impact.
ICHANGE scientists contribute to foundational research exploring the cellular and molecular drivers of obesity-related GI disease, liver steatosis (fat), and metabolic syndrome. This work supports the development of biomarkers and potential therapeutic targets.
Our research program is powered by partnerships across disciplines, including metabolic medicine, nutrition science, and hepatology. This collaborative framework enhances study design, expands research capacity, and drives innovation from bench to bedside.
Patients may be eligible to participate in ongoing clinical trials aligned with their health needs and treatment goals. Our experienced research team provides comprehensive support throughout the process.
If you are interested in learning more about current research initiatives, please contact us at gihepresearch@med.cornell.edu.
